Abstract:Min Du, 1 Jianbo Yin 2 1 Department of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu Province, 214000, People's Republic of China; 2 Department of Pharmacy, Wuxi Dashan Medical Beauty Clinic, Wuxi, Jiangsu Province, 214001, People's Republic of China Correspondence: Jianbo Yin, Email Purpose: Cisplatin (CDDP) and etoposide (Etp) are recommended first-line therapy for lung cancer. Nanostructured lipid carriers (NLCs) are engineered to deliver drugs for lung cancer treatment. In the present study, NLCs were applied to coload an Etp prodrug (EtpP) and CDDP. Methods: The Etp prodrug was synthesized by linking the phenolic hydroxyl group of Etp with polyethylene glycol (PEG). EtpP and CDDP coencapsulated NLCs (EtpP–CDDP NLCs) were prepared using film ultrasound. Cytotoxicity of drugs and drug-containing NLCs was assessed by evaluating cell viability using MTT assays. In vivo antitumor efficiency of EtpP–CDDP NLCs was evaluated on lung cancer–bearing xenografts. Results: EtpP–CDDP NLCs showed a uniformly spherical morphology with a size of 176.8± 4.9 nm and -potential of – 31.9± 3.2 mV. Cellular uptake efficiency of EtpP–CDDP NLCs was 57.4%± 3.9% on A549/DDP cells. EtpP–CDDP NLCs exhibited more sustained plasma retention, the highest drug distribution in tumors, and the highest tumor-inhibition rates in lung tumor–bearing mice. Conclusion: EtpP–CDDP NLCs improved tumor-cell uptake, cytotoxicity, and tumor-inhibition efficiency, and could be used as a promising drug-delivery system for lung cancer combination therapy. Keywords: lung cancer, prodrug, etoposide, cisplatin, nanostructured lipid carriers Lung cancer is the leading cause of cancer death in developed countries, and can be divided into two major classes: non–small cell lung cancer (NSCLC; about 85%) and small-cell lung cancer (about 15%). 1–3 Patients with NSCLC have low overall relative 5-year survival: 25% in the US from 2009 to 2015. 4 On the basis of clinical studies, the National Comprehensive Cancer Network NSCLC Panel recommends cisplatin (CDDP) combined with docetaxel, etoposide (Etp), gemcitabine, or vinorelbine for preoperative and postoperative chemotherapy. 5–7 Arriagada et al found that CDDP plus Etp in patients with completely resected NSCLC improved patient survival by 56.5%. 5 Senan et al used Etp 50 mg/m 2 and CDDP 50 mg/m 2 intravenously on patients with stage IIIA/B unresectable nonsquamous NSCLC randomly. 7 Unfortunately, these nonselective combination chemotherapies with multidrug resistance hindered clinical application. Therefore, major efforts have focused on the development of targeted drug-delivery systems based on prodrugs, nanocarriers, and ligand-modified nanoparticles. CDDP combined with Etp is recommended first-line therapy for NSCLC. 5 CDDP is a cytotoxic antitumor drug. Its main mechanism involves the binding of genomic DNA in the cell nucleus and interfering with transcription to lead to cell death. 8 Its main side effects are nephrotoxicity and peripheral neuropathy. Recently, studies reported that targeted nanocarriers could enhance CDDP's efficacy and reduce its toxicity in healthy cells. 9,10 The topoisomerase II inhibitor Etp inhibits DNA production by affecting the premitotic phase of cell division. 11 Poor solubility and chemical instability are major limits to its clinical application. 12 A prodrug is a kind of compound containing a parent drug that carries out biotransformation in vivo through chemical or enzymatic cleavage, and can effectively transfer active molecules. 13 Prodrug approaches have been developed to modify solubility, increase therapeutic efficacy, and reduce toxicity. 14 Schmidt et al synthesized a glucuronide-based prodrug of Etp that exhibited less cytotoxicity and more water-solubility than Etp itself. 15 In this study, we designed a novel amphiphilic Etp prodrug and tested it on a hydrophobic group (Etp group) and a hydrophilic group (polyethylene glycol, PEG). Nanoparticles have a length of about 1–100 nm. 16 Nanoparticles are attractive for drug delivery because they have important and unique characteristics, such as much larger surface area:mass ratio than other particles, quantum properties, and the ability to adsorb and carry other compounds. 17 Nanoparticles have been exploited to enhance the pharmacokinetic properties and therapeutic effects of drugs. 18 Lipid nanoparticles are colloidal particles composed of biocompatible and biodegradable lipid matrices, among which nanostructured lipid carriers (NLCs) constituted of blends of lipids in solid and liquid state -Abstract Truncated-

Preparation of PEGylated nedaplatin liposomes with sustained release behavior for enhancing the antitumor efficacy of non-small cell lung cancer

The Combination of MnO2@Lipo-coated Gefitinib and Bevacizumab Inhibits the Development of Non-Small Cell Lung Cancer.

Nanodelivery of a Self-Assembling Prodrug with Exceptionally High Drug Loading Potentiates Chemotherapy Efficacy.

Poly(l-glutamic acid)-cisplatin nanoformulations with detachable PEGylation for prolonged circulation half-life and enhanced cell internalization

Preparation of etoposide liposomes for enhancing antitumor efficacy on small cell lung cancer and reducing hematotoxicity of drugs

Co-delivery of paclitaxel and tetrandrine via iRGD peptide conjugated lipid-polymer hybrid nanoparticles overcome multidrug resistance in cancer cells

DACHPt-Loaded Nanoparticles Self-assembled from Biodegradable Dendritic Copolymer Polyglutamic Acid-b-D-α-Tocopheryl Polyethylene Glycol 1000 Succinate for Multidrug Resistant Lung Cancer Therapy

Enhanced Codelivery of Gefitinib and Azacitidine for Treatment of Metastatic-Resistant Lung Cancer Using Biodegradable Lipid Nanoparticles

Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment

Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy

In Vivo Evaluation of Cisplatin-Loaded PEG-PCL Block Copolymeric Nanoparticles for Anticancer Drug Delivery

Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer

Erythrocyte Membrane-Wrapped Ph Sensitive Polymeric Nanoparticles for Non-Small Cell Lung Cancer Therapy.

Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer

Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy

Dual-drug loaded nanoformulation with a galactosamine homing moiety for liver-targeted anticancer therapy.

Dual-Drug Nanosystem: Etoposide Prodrug and Cisplatin Coloaded Nanostructured Lipid Carriers for Lung Cancer Therapy

Prominent Enhancement of Cisplatin Efficacy with Optimized Methoxy Poly(ethylene Glycol)-Polycaprolactone Block Copolymeric Nanoparticles.

Branched PEG-modification: A new strategy for nanocarriers to evade of the accelerated blood clearance phenomenon and enhance anti-tumor efficacy

Lipid-assisted PEG- b-PLA nanoparticles with ultrahigh SN38 loading capability for efficient cancer therapy

Metronomic paclitaxel-loaded mPEG–PLA nanoparticles show enhanced anti-tumor efficacy compared to maximum tolerated dose administration